← Open Payments lookup

FAISAL SUBA: Open Payments

NPI 1598965998 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$3,163 in 146 payments from 18 companies in 2025. Trend: 2023 $1,865 · 2024 $2,091 · 2025 $3,163

Food & beverage: $3,163
CompanyPaymentsAmount
Neurocrine BioSciences, Inc.12$543
Otsuka America Pharmaceutical, Inc.30$500
Alkermes, Inc.13$387
Teva Pharmaceuticals USA, Inc.11$347
E.R. Squibb & Sons, L.L.C.11$241
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)18$188
ABBVIE INC.13$178
Janssen Pharmaceuticals, Inc7$160
Takeda Pharmaceuticals U.S.A., Inc.5$134
Axsome Therapeutics, Inc.5$109

Products named: INGREZZA, REXULTI, ARISTADA, COBENFY, CAPLYTA, UZEDY, VRAYLAR, AUSTEDO XR.

Industry payments across NV — which companies pay providers there.